This session will identify expectations of industry for INDs and marketing applications regarding racial and ethnic enrollment into clinical trials, demographic analyses, and FDAISA requirements on FDA. It will also discuss policy implications for global development, health disparities, and meaningful inclusion of demographic subgroups (sex, race, ethnicity, age) and current Office of Minority Health initiatives in collaboration and advancing regulatory science.